Compare Ishares Msci Italy ETF (EWI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs ResMed Inc. — how do they compare? Ishares Msci Italy ETF trades at $56.2 (market cap $1.14B), while ResMed Inc. trades at $229.22 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 28× Ishares Msci Italy ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 52 Days and ResMed Inc. for 51 Days on average.
| EWI | RMD | |
|---|---|---|
Market Cap | $1.14B | $31.89B |
Volume | 2,377,947 | 618,314 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $277.88 |
52-Week Low | $50.31 | $182.82 |
Typical Hold Time | 52 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
